Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 주웅 | * |
dc.contributor.author | 안정혁 | * |
dc.contributor.author | 성혜윤 | * |
dc.date.accessioned | 2016-12-27T02:12:52Z | - |
dc.date.available | 2016-12-27T02:12:52Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 0513-5796 | * |
dc.identifier.issn | 1976-2437 | * |
dc.identifier.other | OAK-19791 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/233264 | - |
dc.description.abstract | Purpose: Ovarian cancer (OC) is the most fatal of gynecological malignancies with a high rate of recurrence. We aimed to evaluate the expression of solute carrier family 6, member 12 (SLC6A12) and methylation of its promoter CpG sites in a xenograft mouse model of metastatic OC, and to investigate the regulatory mechanisms that promote aggressive properties during OC progression. Materials and Methods: Expression of SLC6A12 mRNA was determined by reverse-transcription quantitative polymerase chain reaction (RT-qPCR), and DNA methylation status of its promoter CpGs was detected by quantitative methylation-specific PCR. The metastatic potential of SLC6A12 was evaluated by in vitro migration/invasion transwell assays. Gene expression and DNA methylation of SLC6A12 and clinical outcomes were further investigated from publicly available databases from curatedOvarianData and The Cancer Genome Atlas. Results: SLC6A12 expression was 8.1-14.0-fold upregulated and its DNA methylation of promoter CpG sites was 41-62% decreased in tumor metastases. After treatment with DNA methyltransferase inhibitor and/ or histone deacetylase inhibitor, the expression of SLC6A12 was profoundly enhanced (similar to 8.0-fold), strongly supporting DNA methylation-dependent epigenetic regulation of SLC6A12. Overexpression of SLC6A12 led to increased migration and invasion of ovarian carcinoma cells in vitro, approximately 2.0-fold and 3.3-fold, respectively. The meta-analysis showed that high expression of SLC6A12 was significantly associated with poor overall survival [hazard ratio (HR)=1.07, p value=0.016] and that low DNA methylation levels of SLC6A12 at specific promoter CpG site negatively affected patient survival. Conclusion: Our findings provide novel evidence for the biological and clinical significance of SLC6A12 as a metastasis-promoting gene. | * |
dc.language | English | * |
dc.publisher | YONSEI UNIV COLL MEDICINE | * |
dc.subject | Ovarian cancer | * |
dc.subject | metastasis | * |
dc.subject | mouse xenograft | * |
dc.subject | SLC6A12 | * |
dc.subject | DNA methylation | * |
dc.title | Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 58 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 27 | * |
dc.relation.lastpage | 34 | * |
dc.relation.journaltitle | YONSEI MEDICAL JOURNAL | * |
dc.identifier.doi | 10.3349/ymj.2017.58.1.27 | * |
dc.identifier.wosid | WOS:000396378400004 | * |
dc.identifier.scopusid | 2-s2.0-84995752746 | * |
dc.author.google | Sung, Hye Youn | * |
dc.author.google | Yang, San-Duk | * |
dc.author.google | Park, Ae Kyung | * |
dc.author.google | Ju, Woong | * |
dc.author.google | Ahn, Jung-Hyuck | * |
dc.contributor.scopusid | 주웅(8873659700) | * |
dc.contributor.scopusid | 안정혁(35081632000) | * |
dc.contributor.scopusid | 성혜윤(57197173696) | * |
dc.date.modifydate | 20240130120134 | * |